VAXIL BIO LTD. announced that further to press release dated October 26, 2020, in respect to cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases, the company has completed the manufacturing of Corvax product for this research project, which is expected to arrive at USAMRIID by the end of this week. The Company further notes that it has initiated an exploratory pre-clinical study to determine the viability of administering Corvax orally. Results from this work are anticipated in January 2021.